An interventional study of The RESILIENT scoliosis brace system in Idiopathic Scoliosis, sponsored by Thinks Works, PBC. Recruiting at 1 site in United States. Open to participants aged 9 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Thinks Works, PBC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Scoliosis with a site in United States — 42 open to participants now, 51 under way, 2 of them phase 3. Scoliosis · United States.
Among the 153 studies in Scoliosis with a site in United States, this one is the 63rd largest by planned enrollment of the 91 interventional ones that give a count, is one of 5 that started in 2026, is one of 65 with no phase, reaches primary completion later than 42 of the 50 other live ones, and was the 148th registered.
660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.
Browse Scoliosis studies →42 of the 153 studies in Scoliosis with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Columbia University · Sites in United States
Ages 10–19
Senthil Sadhasivam · Sites in United States
Ages 10–18
Children's Hospital Los Angeles · Sites in United States
Ages 8–18
Baylor College of Medicine · Sites in United States
Ages 8–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.
This study: 9 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 6 · Phase 4 15
First in 1998; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 45 across 386 interventional studies indexed under Scoliosis.
Median enrollment 58 across the 91 interventional studies, 100 across the 62 observational. Of the 85 that completed or were terminated, 35 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 153 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Thinks Works, PBC as lead sponsor.
Thinks Works, PBC has 1 study filed under Scoliosis — fewer than ten, so there is no comparison to draw.
20 of the studies in Scoliosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217873Phase 3Columbia UniversityIntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study | 2027-08-31 |
| NCT00738439International Spine Study Group FoundationProspective, Multi-Center Adult Spinal Deformity Outcomes Database Registry | 2026-12 |
| NCT06910228Joseph D. TobiasChanges in Cerebral Oxygenation Related to Intraoperative Position Changes | 2026-12 |
| NCT06365892University of California, San FranciscoOpen-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis | 2026-12 |
| NCT03017755Mayo ClinicScoliosis Survey to Development Treatment Decision Tool | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 153 studies in Scoliosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the RESILIENT Scoliosis Brace System works to treat children with idiopathic scoliosis. It will also learn about the safety, comfort, and usability of the brace. The main questions it aims to answer are:
Researchers will study a single group of participants using the RESILIENT brace and evaluate outcomes over time using standard clinical assessments, including X-rays and patient-reported questionnaires.
Participants will:
Participants will be followed from the start of brace treatment until they are done growing and have completed treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be fitted with a novel semi-rigid, low-profile, adjustable, and modular scoliosis brace with embedded sensors measuring force and wear time.
Device: The RESILIENT scoliosis brace system
The RESILIENT brace is a novel semi-rigid (flexible), concealable, adjustable and modular brace with embedded sensors measuring force and wear time.
Also known as: The RESILIENT brace
Treatment Success Based on Curve Progression at Skeletal Maturity
Treatment success is defined as a right main thoracic Cobb angle less than or equal to 35 degrees at skeletal maturity. Treatment failure is defined as progression of the curve to greater than 35 degrees at any time during the treatment period. Cobb angle measurements are obtained from standing posteroanterior spine radiographs and assessed by independent reviewers blinded to patient information. Skeletal maturity is defined as a Sanders Skeletal Maturity Score of ≥7B, absence of longitudinal height increase over the preceding 6 months, and, for female participants, at least 18 months post-menarche.
Time frame: From baseline to skeletal maturity (approximately up to 36 months)
In-Brace Curve Correction at Initial Follow-up
Percent reduction in the primary right main thoracic Cobb angle on standing in-brace posteroanterior spine radiographs obtained at the 4- to 6-week follow-up visit, compared with baseline standing radiographs obtained prior to brace treatment.
Time frame: 4 to 6 weeks
Measurement of brace use compliance as a percentage of prescribed use.
Percent compliance with prescribed daily brace wear time and prescribed apex strap force, as measured by force sensors integrated into the brace and recorded in the monitoring system.
Time frame: From brace initiation through completion of treatment, approximately up to 36 months
Change in Curve Magnitude Following Completion of Brace Treatment
Percent change in the primary right main thoracic Cobb angle from baseline to the final follow-up radiograph obtained after brace discontinuation.
Time frame: From baseline to 4 to 6 months after brace discontinuation
PROMIS Pediatric Quality of Life Scores
Patient-reported outcomes measured using PROMIS pediatric modules. Theses are rated using a numeric rating scale. Physical function-mobility is scored 1-4 with 4 being the best outcome score. Peer relationships is scored 1-5 with 5 being the best outcome score. Depressive symptoms is scored 1-5 with 1 being the best outcome score.
Time frame: Baseline and longitudinal follow-up visits throughout the study, approximately up to 36 months
Scoliosis Research Society-22 (SRS-22) Score
Patient-reported scoliosis-related quality of life measured using the SRS-22 questionnaire.
Time frame: Baseline and longitudinal follow-up visits throughout the study, approximately up to 36 months
Patient and Parent Clinical Trial Completion Exit Survey
When the patient has completed the clinical trial the patient and parent(s)/guardians will be given a survey to assess their overall experience with the brace treatment. It has questions with numerical rating scores from 1-5 with 1 being the best outcome score and questions with descriptive ratings from very positive-very negative, strongly agree-strongly disagree, very likely-very unlikely, extremely willing-not willing.
Time frame: This survey will be given to patients at the completion of their participation in the study, approximately 24 months.
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.
Of 234 interventional studies with no phase under Scoliosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.